Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study

Mehnert, J M; Rugo, H S; O’Neill, B H; Santoro, A; Schellens, J H M; Cohen, R B; Doi, T; Ott, P A; Pishvaian, M J; Puzanov, I; Aung, K L; Hsu, C; Le Tourneau, C; Soria, J; Elez, E; Tamura, K; Gould, M; Zhao, G; Stein, K; Piha-Paul, S A